Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HATCY phase III study of ATIR101 versus post-transplant cyclophosphamide after haploidentical HSCT
NL-OMON48941Phase 3Not yet recruiting
- Sponsor
- Kiadis Pharma
- Start
- Nov 2017
- Modality
- Small Molecules, CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL) and myelodysplastic syndrome (MDS) comparing ATIR101 arm with PTCy arm (2 arms). Primary endpoint: GVHD-free, relapse-free survival. Planned start Nov 2017; status: not yet recruiting.
02
Drugs
ATIR101cyclophosphamide
03
Conditions
acute myeloid leukemia (AML)acute lymphoblastic leukemia (ALL)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NL-OMON48941.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON48941.